Skip to main content
Clinical Trials/CTRI/2025/08/093086
CTRI/2025/08/093086Not yet recruitingPhase 2/3

Evaluation of the efficacy of Mandura Makshika Bhasma in the management of Garbhini Pandu w s r to Iron deficiency anaemia in pregnancy a Randomized controlled clinical trial

Dr Pragya Singh1 site in 1 country36 target enrollmentStarted: September 20, 2025Last updated:

Trial Snapshot

Phase
Phase 2/3
Status
Not yet recruiting
Sponsor
Enrollment
36
Locations
1
Primary Endpoint
Improvement in hematological parameters and clinical

Study Overview

Brief Summary

Anaemia affects 52 percentage of pregnant women in India with Iron Deficiency Anaemia IDA responsible for about half of these cases contributing significantly to maternal and perinatal complications

Conventional treatment involves oral iron supplements which are effective but often poorly tolerated due to gastrointestinal side effects leading to low adherence

Parenteral iron therapy is faster but expensive and risky

In Ayurveda although Garbhini Pandu isnt directly mentioned related conditions like Vivarnata and Pandutwa are discussed

Traditional Ayurvedic medicines like Mandura Bhasma and Swarna Makshika Bhasma have been used to manage anaemia

A unique formulation  Mandura Makshika Bhasma  combines both enhancing therapeutic effects especially for severe pitta related conditions

Despite the availability of modern formulations like ferrous ascorbate side effects and poor bioavailability remain issues

Limited research exists on the combined effects of Mandura and Swarna Makshika Bhasma This study aims to explore their synergy absorption and potential as an effective Ayurvedic alternative for managing IDA in pregnancy

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 40.00 Year(s) (—)
Sex
Female

Inclusion Criteria

  • Confirmed diagnosis of Mild Iron Deficiency Anaemia 9 to 10 point 9 g per dl as per WHO criteria Pregnant women in early second trimester between 14 weeks to 20 weeks 6 days Age group 18 to 40 years Singleton intrauterine pregnancy Willingness to participate.

Exclusion Criteria

  • Moderate to Severe Anaemia Moderate 7 to 8 point 9 g per dl Severe less than 7g per dl Anaemia due to other causes such as megaloblastic anaemia thalassemia or sickle cell anaemia Multiple pregnancy Gestational age less than 14 weeks or more than 21 weeks Chronic metabolic disorders hypertension diabetes hepatic and renal diseases GDM PIH Bleeding disorders like piles peptic ulcer oesophageal varices.

Outcomes

Primary Outcomes

Improvement in hematological parameters and clinical

Time Frame: Baseline 22nd Day and 45th Day

symptoms of Garbhini Pandu

Time Frame: Baseline 22nd Day and 45th Day

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Dr Pragya Singh
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr Pragya Singh

KAHERS Shri B M Kankanawadi Ayurveda Mahavidyalaya

Study Sites (1)

Loading locations...

Similar Trials